With more than one-fifth of the world’s population, China is an important market for biotech products and is increasingly a key global player in biotech research, development and manufacturing. Furthermore, China has made growing the biotech industry one of its top national priorities.
Scientific American’s Worldview 2011 assesses individual countries’ efforts in trying to build and grow biotech hubs. This year’s report focused on the BRIC countries (Brazil, Russia, India and China). China’s standing in the report is somewhat of a mixed bag – the country scored high in the education/workforce measurement, the number of published papers, and China’s standing in the overall scores increased this year; China scored low on IP, investment in innovation and overall intensity (measurement of a country’s overall efforts to drive biotech innovation). The overall ranking is 30 among the 48 countries ranked. The real story is behind the numbers, and is largely based on prospects for future growth of the industry within China’s borders.
BIO is hosting the first BIO China International Conference in October to help elucidate the real story behind the numbers. BIO China is an example of how BIO works as a facilitator for the industry, bringing together business leaders, government officials, and other industry representatives to explore the potential for business development opportunities within the country. Through BIO China, BIO hopes to strengthen relationships with members of the Chinese biotech community and with the Chinese government.
BIO China will bring together western and Chinese life sciences companies for networking and deal-making. Life sciences executives from North America, Europe and Asia will meet in Shanghai to explore business opportunities with China's emerging biotech sector.
BIO’s investor and partnering meetings held around the world provide industry leaders with an opportunity to learn about the challenges and opportunities within individual countries and regions, and meet with numerous existing and prospective partners.
Panel sessions highlight the latest issues and trends related to doing business in China. BIO China Sessions will include:
Health and Regulatory
A Bold Initiative to Support Biotechnology – China’s 12th 5 Year Plan
This panel will discuss key aspects of China’s new initiative to support biotechnology. Thursday, October 13th, 9:30am - 10:45am
Advancing Innovation through Healthcare Reform
China’s health reform plan, which expands coverage to millions of residents and augments coverage in urban areas, represents a mammoth undertaking to support improved public health and wellness. This panel will discuss these questions and review the intersection of health reform and new treatments. Wednesday, October 12th, 2:30pm -3:45pm
Panelist:Song Ruilin, Executive President, SINO-PhIRDA
Navigating Changes in China's Registration & Regulatory Process
Representatives from multi-national and local Chinese companies will discuss the registration process for products manufactured in China, import licensing issues for products exported to China, and the connotations of these processes for innovative global drug development. Wednesday, October 12th, 4:00pm - 5:15pm
Panelist: Wen Chang, VP North Asian Regulatory Strategy & China Regulatory Sciences, Bristol-Myers Squibb
Protecting Biotechnology Inventions in China, US and Europe: A Comparative Perspective
The panel will compare what can be patented and the scope of protection in China, EU and the US including protections that are afforded to plants (utility, PVP, etc.). The panel will also explore the impact of changes in patent laws or regulations in each of these jurisdictions on biotechnology patenting. Wednesday, October 12th, 1:00pm - 2:15pm
Thomas T. Moga, Of Counsel, Shook, Hardy and Bacon
Jasemine Chambers, Deputy Administrator for External Affairs at the United States Patent and Trademark Office (USPTO)
Encouraging Innovation through Robust Patent Enforcement
A panel of experts will explore how enforcement of IP can support the goals of the Twelfth Five-Year plan in a competitive global economy. The panel will explore the challenges to enforcement in face of limited resources and will compare and contrast enforcement in the US and China. Wednesday, October 12th, 4:00pm - 5:15pm
Healthcare Reform Implementation in China's Urban Settings: Attaining New Levels of Prevention
Panelists will discuss methods for reaching broader groups in urban areas with vaccines, such as employer programs and increased healthcare settings. In addition, industry and government panelists will share new developments in vaccines targeted to children, adolescents and adults in these areas.Thursday, October 13th, 1:30pm - 2:45pm
Eradicating Vaccine-preventable Diseases in Rural China - A Look at Key Strategies
Government health leaders will discuss current initiatives to bring important vaccines to citizens in rural areas through a focus on preventing high-impact diseases. Representatives from the vaccine non-governmental organization community will share global strategies used to increase vaccination rates that may prove useful in China. Public and private entities working with the government to develop and deliver these vital preventive services will discuss efforts underway in measles, tuberculosis and hepatitis B prevention.Thursday, October 13th, 9:30am - 10:45am
Innovations in Prevention & Treatment: Global Trends in Vaccine Platform Development
Global advances in technologies for new vaccines. Companies will present scientific and clinical data and discuss their approaches to and uses for new platforms.Wednesday, October 12th, 4:00pm - 5:15pm
China: It's a Big DealM&A and drug development deals between Western and Chinese companies are on the rise. This session will profile one of the most high-profile China-West collaborations of the past year. The principal dealmakers from both companies will be on hand to discuss the deal’s development and will offer candid advice for companies pursuing China-West collaborations.Wednesday, October 12th, 10:30am - 11:45am
IPOs - The Boom in China
Investors and other experts on the capital markets in China will convene to discuss IPO boom in China, lessons learned and what this could possibly mean for other healthcare IPOs across the globe. Wednesday, October 12th, 2:30pm - 3:45pm
For the complete program and session descriptions, visit http://bio.org/biochina.